Lung Cancer Chemotherapy

Posts Tagged ‘Market’

Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.These changes and more are addressed in Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:• Histology/Cytology • Immunoassays • Flow Cytometry • Rapid Tests • Molecular Assays • Tissue Arrays • Circulating Tumor Cells • Pharmacodiagnostics Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data ...

Breast cancer is the second most common type of cancer after lung cancer worldwide and the fifth most common cause of cancer death. It is found more in women as compared to men. Worldwide more than one million new cases of breast cancer are found every year. New breast cancer cases are mostly found in North America.Breast cancer is usually found in women over the age of 40 years. Breast cancer cases have risen about 30% in the past 25 years in western countries like the US and Europe. Breast cancer market is comprised of two segments - diagnostic and therapy. The key drivers of breast cancer market are aging population, obesity and family history among others.The stages of breast cancer are of critical importance and decide the treatment method and the extent to which it can be cured. Mammography is believed to find 85% to 90% of breast cancers in women over 50, and can discover a lesion one to four years before a lump can be felt. In case of patients with dense breast tissue, breast implants or patients who are breastfeeding, mammography cannot produce clear images and therefore, in such cases, ultrasound or MRI is recommended. Biopsy ...

Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics. In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin. At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the premise on which the entire biopharmaceutical industry has been built. Key features of this report • Epidemiological analysis and forecast prevalence of the major cancer indications over the period 2008-14 including lung, breast, colorectal, ovarian cancer markets. • Forecasts ...

In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics. In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin. At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the ...

The industry analysis specialist's new report, "Non-Small Cell Lung Cancer (NSCLC) – Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global NSCLC disease market. The report identifies the key trends shaping and driving the global NSCLC disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC disease sector.This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  team of industry experts.  estimates the global NSCLC disease market to be $2.8 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 13.5% for the next seven years to reach $6.8 billion by 2015. This growth is primarily attributed to increased disease population and strong pipeline with more emerging therapies. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the ...

DescriptionThe industry analysis specialist's new report, "Non-Small Cell Lung Cancer (NSCLC) - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global NSCLC disease market. The report identifies the key trends shaping and driving the global NSCLC disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC disease sector.This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimates the global NSCLC disease market to be $2.8 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 13.5% for the next seven years to reach $6.8 billion by 2015. This growth is primarily attributed to increased disease population and strong pipeline with more emerging therapies. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the ...

Lung Cancer Therapeutics Market Outlook and Pipeline Analysis  With over 50% of all non-small cell lung cancer (NSCLC) patients diagnosed at the advanced stages of the disease, and 95% of all small-cell lung cancer (SCLC) patients unsuitable for surgical resection, drug therapy plays a vital role in the management of lung cancer. Such high level of unmet need ensures the lung cancer market is an attractive commercial opportunity for new drug development. ( http://www.bharatbook.com/detail.asp?id=132820&rt=Lung-Cancer-Therapeutics-Market-Outlook-and-Pipeline-Analysis.html )  Lung Cancer Therapeutics Market & Pipeline Analysis supports the process of successful product development and commercialization within the pharmaceutical/biopharmaceutical lung cancer market by addressing the following key areas:  * Epidemiology of lung cancer  * Current lung cancer treatments  * Analysis of current lung cancer therapeutics  * Unmet needs within the lung cancer market  * Research and development (R&D) approaches towards lung cancer  * Pipeline analysis of key lung cancer candidates  * Forecast sales of key pipeline lung cancer candidates   The report also analyzes the market status and potential for the following key lung cancer therapies:  * Sanofi-Aventis' Taxotere (docetaxel)  * Eli-Lilly's Gemzar (gemcitabine)  * Eli-Lilly's Alimta (pemetrexed)  * GlaxoSmithKline's Hycamtin (topotecan) (SCLC therapeutic)  * OSI Pharmaceuticals/Roche's Tarceva (erlotinib)  * AstraZeneca's Iressa (gefitinib)  * Roche's Avastin (bevazicumab)   and the market ...